Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check. Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin. The two companies partnered to incorporate and integrate […]
Big Data
Data supports digital diabetes program from Carbon Health
Carbon Health today announced patient data from its digital diabetes program, highlighting improved outcomes. San Francisco-based Carbon Health designed its endocrinologist-led platform to integrate with primary care. A certified team of diabetes educators supports the completely virtual platform. It offers accessibility to patients with no waiting or travel time involved. Carbon Health’s electronic health record […]
JDRF launches Type 1 Diabetes Index simulation tool
JDRF announced today that it launched the Type 1 Diabetes Index (T1D Index) data simulation tool for measuring the impact of T1D around the globe. The tool measures the human and public health impact type 1 diabetes has in every country. JDRF said it addresses wide gaps in data about the incidence and impact of […]
Study backs automated insulin delivery system from Diabeloop
Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low. The company said in a news release that the results, combined with trust in its algorithm, […]
Better Therapeutics completes trial for type 2 diabetes treatment, will submit to FDA
Better Therapeutics (Nasdaq:BTTX) announced today that it completed the pivotal trial for its BT-001 digital therapeutic for diabetes. San Francisco-based Better Therapeutics designed its nutritional cognitive behavioral therapy (nCBT) platform to address the root causes of cardiometabolic diseases. It designed its investigational, first-in-class BT-001 prescription digital therapeutic (PDT) to use nCBT to treat type 2 […]
Study backs One Drop’s AI-powered blood glucose forecasts in diabetes outcomes
One Drop announced today that a study of its AI-powered blood glucose forecasting technology leads to improved diabetes outcomes. New York-based One Drop published outcomes from a retrospective cohort study in the Journal of Medical Internet Research (JMIR). The study focused on indicators of glycemic control and health data logging in adults with type 2 diabetes using […]
Readout Health wins JDRF grant to evaluate handheld breath ketone monitor
Readout Health announced today that it entered into a sponsored research agreement with Washington University School of Medicine. The agreement with Washington University School of Medicine (St. Louis) includes a two-year, $360,000 research grant from JDRF to test the efficacy of the Biosense handheld breath ketone monitor in persons with type 1 diabetes during usual […]
Data shows cost benefits with Pear Therapeutics digital therapeutic for opioid use disorder
Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated […]
Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology
Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology. Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. “Our Control-IQ technology continues […]
One Drop studies show improved attitudes toward CGM, diabetes management platform
One Drop announced positive data from multiple studies evaluating the opinions of people with diabetes on continuous glucose monitoring. New York-based One Drop presented new research about attitudes and adoption of continuous glucose monitors (CGMs) among people with type 2 diabetes at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Participants in […]
